BlackBerry Limited vs TransMedics Group Inc — how do they compare? BlackBerry Limited trades at $11.09 (market cap $6.39B), while TransMedics Group Inc trades at $74.59 (market cap $2.58B). The key difference: BlackBerry Limited is far larger — about 2.5× TransMedics Group Inc's market cap, and BlackBerry Limited is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| BB | TMDX | |
|---|---|---|
Market Cap | $6.39B | $2.58B |
Sector | Technology | Technology |
52-Week High | $12.81 | $150.42 |
52-Week Low | $3.15 | $61.99 |
Enterprise Value | $6.26B | $2.98B |
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $10.71, down 2.37% today, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q1 2026 earnings beat expectations with EPS of $0.06 versus $0.05 expected, driven by QNX software growth. Revenue for 2025 was $534.90M with a net loss of $79M, but 2026 projects a return to profitability. Positive news highlights QNX expansion into robotics and industrial automation.
Outlook is cautiously optimistic as the company's turnaround gains traction, but high valuation ratios (P/E 107.1) and mixed analyst sentiment (14% buy, 86% hold) suggest execution risks remain. Key opportunities include QNX's market penetration, while risks involve competitive pressures and achieving sustained profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →